loading...| Preferred Name |
evolocumab |
|
| Synonyms |
antilipemic agent amg 145 amg-145 amg145 evolocumab repatha |
|
| Definitions |
A human immunoglobulin G2 (IgG2) monoclonal antibody directed against human proprotein convertase subtilisin/kexin type 9 (PCSK9), that can be used in the treatment of hypercholesterolemia. Upon administration, evolocumab targets, binds to and inhibits the activity of PCSK9. This prevents binding of PCSK9 to low-density lipoprotein receptor (LDLR) on hepatocytes and prevents its degradation. This increases LDLR on hepatocytes and increases the liver's ability to remove LDL cholesterol (LDL-C) from the blood, thereby lowering LDL-C levels. PCSK9 binds to LDLR on the surface of hepatocytes to promote LDLR degradation within the liver. [url:http://purl.obolibrary.org/obo/NCIT_C174672] |
|
| ID |
http://www.semanticweb.org/admin/ontologies/2022/7/MIO:02169 |
|
| definition |
A human immunoglobulin G2 (IgG2) monoclonal antibody directed against human proprotein convertase subtilisin/kexin type 9 (PCSK9), that can be used in the treatment of hypercholesterolemia. Upon administration, evolocumab targets, binds to and inhibits the activity of PCSK9. This prevents binding of PCSK9 to low-density lipoprotein receptor (LDLR) on hepatocytes and prevents its degradation. This increases LDLR on hepatocytes and increases the liver's ability to remove LDL cholesterol (LDL-C) from the blood, thereby lowering LDL-C levels. PCSK9 binds to LDLR on the surface of hepatocytes to promote LDLR degradation within the liver. [url:http://purl.obolibrary.org/obo/NCIT_C174672] |
|
| label |
evolocumab |
|
| MIO_ID |
MIO:02169 |
|
| prefLabel |
evolocumab |
|
| reference |
NCIT:C174672 SNOMED:716068004 |
|
| synonyms |
antilipemic agent amg 145 amg-145 amg145 evolocumab repatha |
|
| subClassOf |
http://www.semanticweb.org/admin/ontologies/2022/7/MIO:01102 |